

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Akerman et al. Confirmation No.: 6643  
Serial No.: 10/591,214 Group Art Unit No.: 1625  
Filed: August 28, 2006 Examiner: Davis, Zinna Northington  
For: COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND  
METHODS FOR USE IN TREATING METABOLIC DISORDERS  
Docket No.: A-988-US-PCT

**INFORMATION DISCLOSURE STATEMENT****Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Examiner Davis:

As a means of complying with the duty of disclosure under 37 CFR §§ 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on the attached modified PTO-1449 form and provide a copy of the listed references other than published U.S. patent applications and issued U.S. patents for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

The documents listed on the enclosed modified PTO-1449 form and included herewith include a search report conducted by the Austrian Patent Office and completed on January 2, 2009, and mailed to the Intellectual Property Office of Singapore on January 30, 2009, for a corresponding patent application in Singapore, and two PCT applications which have not previously been submitted with respect to this application. The other three documents (WO 99/11255, US 6,506,757, and WO 2004/000315) cited in the Austrian Patent Office search report have previously been submitted in information disclosure statements with respect to this patent application.

Identification of the listed references is not to be construed as an Admission by Applicants or attorney for Applicants that such references are available or qualify as "prior art" against the subject application. Applicants reserve the right to remove any such reference which the Patent and Trademark Office may cite against the subject application.

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I, Casey Livingston, hereby certify that this paper (along with any referenced to as being attached or enclosed) is being electronically transmitted to the United States Patent and Trademark Office on the date shown below.

9-14-09

Date

Casey Livingston  
Signature

This Information Disclosure Statement is being submitted in compliance with 37 C.F.R. § 1.97(b)(3), before the mailing of a first Office Action on the merits.

Applicants request consideration of this information and passage of the application to issue.

**FEE PAYMENT**


No fee is due for submission of this information disclosure statement because it is filed along with a Request for Continued Examination in compliance with 37 C.F.R. § 1.97(b)(4).

The Commissioner is hereby authorized to charge any additional fee(s) which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

**21069**

Please send all future correspondence to:  
 US Patent Operations/BPF  
 Dept. 4300, M/S 28-2-C  
 AMGEN INC.  
 One Amgen Center Drive  
 Thousand Oaks, California 91320-1799

  
 Bernard P. Friedrichsen  
 Attorney/Agent for Applicant(s)  
 Registration No.: 44,689  
 Phone: (805) 447-0628  
 Date: April 14, 2009